Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Megadott ok: Sponsor's discretion to termination due to business decision.
Key facts
- Where
- Allentown, Birmingham, Broomfield, Burnsville, Chapel Hill, Coon Rapids, Denver, Edina, Greenville, High Point, Houston, Kettering, La Crosse, Lake Charles, Lexington, Madison, Maplewood, Marshfield, Midlothian, Milwaukee, Minneapolis, New Orleans, Newark, Pasadena, Portland, Raleigh, Robbinsdale, Rockford, Rockville, Saint Louis Park, Tacoma, Tupelo, Vallejo, Waukesha és Woodbury, Egyesült ÁllamokSee the 40 sites
Where in Egyesült Államok
- Lehigh Valley Health NetworkAllentown, Egyesült ÁllamokNo longer taking part
- University of Alabama BirminghamBirmingham, Egyesült ÁllamokNo longer taking part
- SCL HealthBroomfield, Egyesült ÁllamokNo longer taking part
- Minnesota Oncology - BurnsvilleBurnsville, Egyesült ÁllamokNo longer taking part
- University of North Carolina, Chapel HillChapel Hill, Egyesült ÁllamokNo longer taking part
- Minnesota Oncology - Coon RapidsCoon Rapids, Egyesült ÁllamokNo longer taking part
- Kaiser Permanente ColoradoDenver, Egyesült ÁllamokNo longer taking part
- Fairview Southdale HospitalEdina, Egyesült ÁllamokNo longer taking part
- Bon Secours St. FrancisGreenville, Egyesült ÁllamokNo longer taking part
- Prisma Health Cancer InstituteGreenville, Egyesült ÁllamokNo longer taking part
- Hayworth Cancer CenterHigh Point, Egyesült ÁllamokNo longer taking part
- UTHealth - Memorial Hemann Cancer InstituteHouston, Egyesült ÁllamokNo longer taking part
- Kettering Health NetworkKettering, Egyesült ÁllamokNo longer taking part
- Gundersen Health SystemLa Crosse, Egyesült ÁllamokNo longer taking part
- Christus HealthLake Charles, Egyesült ÁllamokNo longer taking part
- Baptist HealthLexington, Egyesült ÁllamokNo longer taking part
- University of WisconsinMadison, Egyesült ÁllamokNo longer taking part
- Minnesota Oncology - Maplewood Cancer CenterMaplewood, Egyesült ÁllamokNo longer taking part
- St. John's HospitalMaplewood, Egyesült ÁllamokNo longer taking part
- Marshfield ClinicMarshfield, Egyesült ÁllamokNo longer taking part
- Bon Secours MidlothianMidlothian, Egyesült ÁllamokNo longer taking part
- Aurora Research InstituteMilwaukee, Egyesült ÁllamokNo longer taking part
- Metro-Minnesota Community Oncology Research ConsortiumMinneapolis, Egyesült ÁllamokNo longer taking part
- Minnesota Oncology MinneapolisMinneapolis, Egyesült ÁllamokNo longer taking part
- Regions HospitalMinneapolis, Egyesült ÁllamokNo longer taking part
- Ochsner Clinic FoundationNew Orleans, Egyesült ÁllamokNo longer taking part
- Christiana Care Health SystemNewark, Egyesült ÁllamokNo longer taking part
- Kaiser Permanente Southern CaliforniaPasadena, Egyesült ÁllamokNo longer taking part
- Kaiser Permanente NorthwestPortland, Egyesült ÁllamokNo longer taking part
- UNC Rex HealthcareRaleigh, Egyesült ÁllamokNo longer taking part
- North Memorial Health CareRobbinsdale, Egyesült ÁllamokNo longer taking part
- SwedishAmericanRockford, Egyesült ÁllamokNo longer taking part
- Kaiser Permanente - Mid-AtlanticRockville, Egyesült ÁllamokNo longer taking part
- Minnesota Oncology - EdinaSaint Louis Park, Egyesült ÁllamokNo longer taking part
- Park Nicollet Health ServicesSaint Louis Park, Egyesült ÁllamokNo longer taking part
- MultiCareTacoma, Egyesült ÁllamokNo longer taking part
- North Mississippi Medical CenterTupelo, Egyesült ÁllamokNo longer taking part
- Kaiser Permanente Northern CaliforniaVallejo, Egyesült ÁllamokNo longer taking part
- ProHealth CareWaukesha, Egyesült ÁllamokNo longer taking part
- Minnesota Oncology - Woodbury ClinicWoodbury, Egyesült ÁllamokNo longer taking part
Trial details
- Who runs it
- Strata Oncology
- Trial code
- NCT03061305
- Record updated
- 2025. január 31.
- Original description
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials.Read full original descriptionShow less
An Observational Trial Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials.
The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical trials and approved targeted therapies in advanced and/or aggressive cancers. The Strata Trial uses surplus, or leftover, tumor specimens for molecular profiling and does not require additional study-specific procedures.
Inclusion: Subjects must be ≥ 18 years of age; Subjects must have histologically documented solid tumors (including lymphoma and multiple myeloma); Specific criteria for individual tumor types are as follows:; Participants with gliomas are eligible at any stage of disease; Participants with pancreatic carcinoma are eligible at any stage of disease; Participants with rare tumors (i.e. cancer started in an unusual place in the body, it is unusual type and requires special treatment) are eligible at stages II-IV; Participants with other tumor types must have recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; Participants with other tumor types must have recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; Must have an adequate formalin-fixed paraffin-embedded tumor specimen for genomic sequencing.